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The cytotoxicity of DNA-protein crosslinks (DPCs) is
largely ascribed to their ability to block the progres-
sion of DNA replication. DPCs frequently occur in
cells, either as a consequence of metabolism or
exogenous agents, but the mechanism of DPC repair
is not completely understood. Here, we characterize
SPRTN as a specialized DNA-dependent and DNA
replication-coupled metalloprotease for DPC repair.
SPRTN cleaves various DNA binding substrates dur-
ing S-phase progression and thus protects prolifera-
tive cells from DPC toxicity. Ruijs-Aalfs syndrome
(RJALS) patient cells with monogenic and biallelic
mutations in SPRTN are hypersensitive to DPC-
inducing agents due to a defect in DNA replication
fork progression and the inability to eliminate
DPCs. We propose that SPRTN protease represents
a specialized DNA replication-coupled DPC repair
pathway essential for DNA replication progression
and genome stability. Defective SPRTN-dependent
clearance of DPCs is the molecular mechanism un-
derlying RJALS, and DPCs are contributing to accel-
erated aging and cancer.
INTRODUCTION
Numerous endogenous and exogenous factors constantly
attack the genome causing a variety of chemically distinct DNA
lesions (Lindahl, 1993). If not repaired, such DNA lesions lead
to genomic instability and cell death (Jackson and Bartek,
2009). Cells have evolved multiple DNA repair pathways,704 Molecular Cell 64, 704–719, November 17, 2016 ª 2016 The Aut
This is an open access article under the CC BY license (http://creativespecialized for distinct types of DNA lesions (Friedberg et al.,
2006; Lindahl and Wood, 1999). DNA-protein crosslinks (DPCs)
represent a so far under investigated type of DNA lesion caused
by the covalent attachment of proteins to nucleobases, sugar, or
broken phosphodiester bonds on the DNA backbone (Ashour
et al., 2015; Tretyakova et al., 2015). Very little is known about
how cells remove DPCs and repair DPC-induced DNA lesions
(Barker et al., 2005; Connelly and Leach, 2004; Stingele and
Jentsch, 2015; Tretyakova et al., 2015). DPCs are induced by
chemical reactions catalyzed by products of cellular metabolism
like aldehydes or by exogenous sources including UV-light and
ionizing radiation (Ide et al., 2011; Shi et al., 2004). Virtually any
protein in close vicinity to DNA could form a non-enzymatic
DPC in the presence of a crosslinking compound such as form-
aldehyde (FA) (Shoulkamy et al., 2012). DPCs are also induced
enzymatically when certain DNA-binding enzymes form transient
covalent interactions with DNA during their physiological reac-
tion cycles. The best-studied enzymatic DPCs are topoiso-
merases 1 and 2a (Topo1 and Topo2a), known as Topo1- or
Topo2a-cleavage complexes (Topo-ccs) (Ashour et al., 2015;
Maede et al., 2014). Topo1-ccs or Topo2-ccs are removed by
tyrosyl-DNA phosphodiesterase-1 or -2 (TDP1 or TDP2), after
proteolysis of Topos into small peptide fragments (max 15–108
amino acids) by an unknown mechanism (Debe´thune et al.,
2002; Interthal and Champoux, 2011). This suggests the exis-
tence of a protease that processes Topos upstream of TDP1
or 2 (Zhang et al., 2006). Despite the frequent occurrence of
endogenous non-enzymatic and enzymatic DPCs in cells, the
mechanism of DPC removal is still largely unknown (Ide et al.,
2015).
Studies in bacteria, yeast, and higher eukaryotes suggest that
several canonical DNA repair pathways, including nucleotide
excision repair, homologous recombination, and Fanconi ane-
mia repair pathway together with proteasome-dependent pro-
tein degradation are involved in the removal of DPCs (Barkerhors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
(legend on next page)
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et al., 2005; de Graaf et al., 2009; Nakano et al., 2007; Salem
et al., 2009). Recently, a yeast DNA-dependent protease Wss1
(weak suppressor of smt3) was shown to protect yeast cells
from FA-induced toxicity and, in coordination with Tdp1, pro-
cess Topo1-ccs (Stingele et al., 2014).
We are currently not aware of any specialized DPC repair
pathway in metazoans, although DPC removal is essential for
DNA replication fork progression (Kuo et al., 2007; Reardon
et al., 2006). Recent biochemical data in Xenopus egg extract
demonstrated that DPC removal is coupled to DNA replication
in a proteasome-independent, but protease-dependent manner
(Duxin et al., 2014). However, the protease required for the
removal of DPCs during DNA replication remained unknown
(Duxin and Walter, 2015; Reardon et al., 2006).
Ruijs-Aalfs syndrome (RJALS), also known as SPARTAN syn-
drome, is a human autosomal recessive disease characterized
by chromosomal instability, premature aging, and early onset
hepatocellular carcinoma in children. RJALS is caused bymono-
genic and biallelic mutations in SPRTN (DVC1), and a single
missense mutation in a putative metalloprotease SprT domain
(SPRTNY117C) is pathogenic and responsible for premature aging
and liver cancer in humans (Lessel et al., 2014; Ramadan et al.,
2016). While the roles of the C-terminal domains of SPRTN
have been extensively characterized in translesion DNA synthe-
sis and recruitment to DNA damage foci, the function of the SprT
domain, localized in the N-terminal part, is completely unknown
(Centore et al., 2012; Davis et al., 2012; Ghosal et al., 2012; Mos-
bech et al., 2012). At the cellular level, RJALS cells exhibit DNA
replication stress, specifically slower replication, and increased
numbers of stalled forks and DNA double-strand breaks (Lessel
et al., 2014).
Given the importance of SPRTN in genome stability, and the
fact that bioinformatic analysis suggests that SPRTN and
the yeast protease Wss1 are both distantly related to the
Zinicin family of metalloproteases (Stingele et al., 2015), we
asked whether SPRTN is a metalloprotease responsible for
DPC repair.
Here, we show that SPRTN is a DNA-dependent protease that
protects human proliferative cells from DPC toxicity. SPRTN as-
sociates with the DNA replication machinery and removes DPCs
during DNA synthesis, and thus RJALS is caused by a defect in
DPC repair. Altogether, we identified the mechanism for DPC
removal from chromatin in human cells and highlighted the
importance of this mechanism for genome stability and its rele-
vance for human pathogenesis in accelerated aging and
carcinogenesis.Figure 1. SPRTN Prevents Basal DNA-Protein Crosslinks Accumulatio
(A) Schematic of DPC isolation protocol (RADAR).
(B) DPC accumulation in HeLa cells after FA treatment (2.5 mM, 30min).
(C) SPRTN deficiency leads to DPCs accumulation (silver staining). The quantific
(D) Quantification of DPC isolates by SDS/KCl precipitation method.
(E) Schematic of SPRTN protein domains and a putative protease active site.
(F) Schematics of biallelic SPRTN mutations in RJALS patients.
(G) Total DPC levels after ectopic expression of SPRTN WT or E112A in D-SPRT
(H) Total DPC levels in RJALS patient LCLs from family B (two patients; B-II:1 an
shown (right image). Mean ± SEM, n = 3.
See also Figure S1.
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SPRTN Prevents Accumulation of Endogenous
DNA-Protein Crosslinks
To investigate the role of SPRTN in DPC repair, we isolated
total genomic DNA from HeLa cells and analyzed the amount
of DPCs using rapid approach to DNA adducts recovery
(RADAR) coupled to SDS-PAGE/silver staining (Figure 1A) (Kiia-
nitsa and Maizels, 2013). The isolation of DNA under stringent
denaturing conditions allows us to exclusively detect proteins
that are crosslinked to DNA (DPCs). DPC isolates were quanti-
fied for total DNA amount to ensure equal amount of DNA for
DPC analysis and then treated with Benzonase, to remove all
DNA and RNA, prior to SDS-PAGE/silver staining detection.
Proteinase K treatment of Benzonase-treated DPCs confirms
specificity of protein staining by the silver-staining method
(Figure S1A). In addition, treating the cells with FA, camptothe-
cin (CPT), or etoposide (ETO), known DPC-inducing agents, as
expected causes a huge accumulation of general (Figure 1B) or
specific DPCs (Figure S1B).
Quantitative analysis of total DPCs by silver staining in
different cell lines (HeLa, HEK293, and T24) revealed that SPRTN
depletion resulted in a 2- to 5-fold increase in the total amount of
proteins covalently attached to DNA (Figures S1C and S1D and
data not shown). Similarly, CRISPR/Cas9-created SPRTN partial
knockout HeLa cells (D-SPRTN, Figures S1E–S1G) showed a 3-
to 4-fold increase in total DPCs (Figure 1C). Accumulation of
DPCs observed in D-SPRTN cells was further confirmed by
SDS/KCl precipitation assay, an indirect method for DPC isola-
tion (Figure 1D). The increase in DPCs in SPRTN-deficient cells
was not due to differences in cell-cycle stage (Figures 1C,
S1C, and S1D). To investigate if a putative protease domain in
SPRTN plays a role in DPC removal, we ectopically expressed
SPRTN wild-type (SPRTNWT) or E112A (SPRTNE112A), a variant
containing a glutamic acid to alanine change in a predicted pro-
tease active center (HEXXH, H; histidine, E; glutamic acid, X; and
any amino acid; Figure 1E), in D-SPRTN HeLa cells. Overexpres-
sion of SPRTNWT, but not SPRTNE112A, completely rescued
basal DPC accumulation (Figure 1G, compare lanes 3 and 4).
To investigate whether RJALS lymphoblastoid cell lines (LCLs)
with monogenic and biallelic mutations in SPRTN (Figure 1F;
SPRTN-DC/SPRTNY117C) are also deficient in removal of
DPCs, we isolated and analyzed total DPCs in these cells (Fig-
ure 1H). RJALS cells showed a 1.5- to 2-fold increase in total
DPCs when compared to control LCLs (Figure 1H, compare
lane 1 to lanes 2 and 3).n
ation and cell-cycle profiles are shown (right images).
N HeLa cells and corresponding quantification. whole cell extract: WCE.
d B-II:4) and control LCLs (CTR). The quantification and cell-cycle profiles are
Figure 2. RJALS and SPRTN-Depleted Cells Are Hypersensitive to DPC-Inducing Agents
(A) Cell viability assays of RJALS (B-II:1 and B-II:4) and control (CTR) LCLs after treatment with indicated chemicals.
(B) Clonogenic survival assay of siRNA control (CTR) or siRNA SPRTN-depleted HeLa cells after treatment with indicated chemicals.
(legend continued on next page)
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The nucleotide excision repair (NER) and homologous recom-
bination (HR) pathways have also been implicated in DPC repair.
However, depletion of the main components of NER (XPC) and
HR (MRE11) by small interfering (si)RNA did not lead to an in-
crease to the total amount of DPCs (Figure S2A). Similarly,
impairment of the DNA interstrand crosslink repair pathway,
Fanconi anemia, by depletion of FANCD2 did not cause DPC
accumulation compared to control cells (Figure S2A). Altogether,
these results indicate that SPRTN is the main player involved in
DPC removal, and, more specifically, that its putative metallo-
protease active residue (E112), is essential for removal of endog-
enously occurring DPCs in human proliferative cells.
RJALS and SPRTN-Depleted Cells Are Hypersensitive to
DPC-Inducing Agents
We further asked whether RJALS patient LCLs and siRNA
SPRTN-depleted HeLa cells are hypersensitive to DPC-inducing
agents. We used FA and methylglyoxal, which induce general
DPCs (Figure 1B and data not shown), and CPT and ETO, which
induce specific enzymatic DPCs (Figure S1B). Both RJALS pa-
tient cells (Figure 2A) and SPRTN-depleted cells (Figures 2B
and S2B) were hypersensitive to DPC-inducing agents. To
analyze how individual SPRTN mutations found in RJALS pa-
tients affect cell sensitivity to DPC-inducing agents, we created
doxycycline (DOX) inducible and stable Flp-In HeLa cell lines, ex-
pressing wild-type (WT), enzymatic dead protein (E112A), and
patient variants of SPRTN (Figures 2C–2H and S2C–S2F).
Ectopic expression of SPRTNWT, where endogenous SPRTN
was depleted with siRNA targeting the 30 UTR of SPRTN tran-
scripts, rescued SPRTN-depleted cells’ hypersensitivity to FA
(Figure 2D) or CPT (Figure S2C). Conversely, overexpression of
SPRTNE112A or patient variant SPRTNY117C was not able to
rescue hypersensitivity to FA (Figures 2E and 2F, respectively)
or CPT (Figures S2D and S2E, respectively). Ectopic expression
of the truncated patient variant SPRTN-DC, which still contains
an intact putative metalloprotease domain, partially rescued hy-
persensitivity to FA (Figure 2G) or CPT (Figure S2F). Both patient
mutations are defective in their ability to protect cells fromDPCs,
although SPRTN-DC to a lesser extent, since RJALS LCLs are
hypersensitive to DPC-inducing agents (Figure 2A).
Next, to address if the cytotoxicity observed in SPRTN-defi-
cient cells is due to accumulation of DPCs, we co-depleted
Topo1 and SPRTN and monitored cell survival following CPT
treatment. Co-depletion of Topo1 completely rescued sensitivity
to CPT in SPRTN-depleted cells (Figure S2G), confirming that
CPT-induced toxicity in SPRTN-depleted cells is due to accumu-
lation of Topo1-ccs. Co-depletion of TDP1, a key player in
Topo1-cc removal, does not further hypersensitize SPRTN-
depleted cells to CPT, suggesting that both proteins work in
the same pathway (Figure S2H).
The Fanconi anemia pathway is known to protect from
formaldehyde-induced toxicity. As expected, inactivation of
the Fanconi anemia pathway by FANCD2 siRNA depletion hy-(C) Schematic of experimental setup for clonogenic survival assays in doxycyclin
(D–G) Ectopic expression of SPRTNWT (D), SPRTNE112A (E), SPRTNY117C (F), and
(H) Western blot (WB) demonstrating SPRTN depletion and/or overexpression. M
See also Figure S2.
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ure S2I). This further suggests that the Fanconi anemia pathway
is strictly involved in repair of DNA-interstrand crosslinks (also
induced by FA treatment), but not DNA-protein crosslinks (e.g.,
removal of a specific DPC induced by CPT). Altogether, these re-
sults suggest that SPRTN forms a uniqueDNA repair pathway for
DPC removal.
SPRTN Is a DNA-Dependent Metalloprotease
Intensive work from several laboratories was unable to identify
SPRTN protease activity (Davis et al., 2012; Kim et al., 2013;
Mosbech et al., 2012). Our results led us to re-evaluate published
data and investigate whether SPRTN is indeed a protease. To
this end, we purified SPRTNWT, SPRTNE112A, two patient vari-
ants (SPRTNY117C and SPRTN-DC), and several C-terminally
truncated variants of SPRTN using an E. coli protein expression
system.
Considering that the SprT domain is classified as a putative
metalloprotease domain, we first analyzed the presence of metal
in the SPRTN protein. We purified SPRTN lacking the C-terminal
Zn-binding UBZ domain and PIP-box (SPRTN 1–268) and
analyzed it by mass spectrometry. Intact protein analysis of
SPRTN under native and denaturing conditions revealed a
mass increase of 126 daltons, which is consistent with the pres-
ence of two zinc ions (Figure S3A). The recent finding that the
yeast protease Wss1 requires DNA to elicit proteolytic activity
(Balakirev et al., 2015; Stingele et al., 2014) led us to investigate
whether SPRTN binds DNA. We used 63 bp double-strand DNA
probes (dsDNA) labeled with fluorescein isothiocyanate (FITC) to
analyze SPRTN binding affinity by fluorescence polarization.
SPRTNWT protein showed high affinity to dsDNA (dissociation
constant [KD] z100 nM) (Figure 3A). In silico analysis of the
SPRTN secondary structure revealed the presence of five DNA
binding regions: four motifs in the C-terminal part of the protein
and one in the SprT protease domain (Figures 3B and S3B).
The removal of predicted C-terminal DNA binding sites strongly
decreased the DNA binding affinity of SPRTN (Figure 3A).
Next, we asked whether SPRTN binds different DNA struc-
tures. SPRTNWT binds single-strand DNA (ssDNA), dsDNA,
and splayed DNA with similar affinities (Figure 3C). SPRTNE112A
and SPRTNY117C exhibited similar affinities to DNA as SPRTNWT.
The truncated variant of SPRTN-DC (1–246) showed reduced
affinity to DNA (KD z 0.48 mM; Figure 3A), which correlates
with the loss of putative DNA-binding sites (Figures 3B and S3B).
We observed increased levels of SPRTNWT degradation when
the reaction of SPRTN and DNA was incubated for a longer
period of time and analyzed by SDS-PAGE/Coomassie blue
staining. Full-length SPRTNWT protein was mostly intact and
ran at the predicted size of 55 kDa (Figure 3D, lane 1). However,
incubation of SPRTNWT with dsDNA induced strong degradation
of SPRTN with several visible protein bands and a prominent
accumulation of a 25 kDa fragment (Figure 3D, lane 2).
Mass spectrometry analysis of SPRTNWT degradation productse inducible (+Dox) SPRTN Flp-In HeLa cell lines.
SPRTN-DC (G) after depletion of endogenous SPRTN.
ean ± SEM, n = 3.
(legend on next page)
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identified at least five different cleavage products in the SPRTN
protein (Figure S7C), with cleavage sites located in its C-terminal
part (Figure S3C). SPRTNWT auto-cleavage activity was inhibited
in the presence of 1,10 phenanthroline, a known inhibitor of Zn2+-
dependent metalloproteases (Figure 3D, lane 3). SPRTN auto-
cleavage activity was abolished by the E112A mutation
(Figure 3D, lane 5). Western blot analysis of SPRTNWT auto-
cleavage products with antibodies raised against N- or C-termi-
nal fragments of SPRTN further confirmed mass spectrometry
data and demonstrated that SPRTN protein was mainly cleaved
within its C-terminal part, while the N-terminal fragment re-
mained mostly intact (Figure 3E, lanes 2 and 5). These data sug-
gest that SPRTN is a DNA and Zn-dependent protease, which
possesses auto-cleavage activity in vitro. SPRTNWT, but not
SPRTNE112A, auto-cleavage products were also visible in
HEK293 cells, especially after FA treatment, demonstrating
SPRTN auto-cleavage activity in vivo (Figure 3F).
We further asked what is the minimum length of DNA required
to activate SPRTN cleavage activity (Figure S3D). Different sized
probes of ss or dsDNA were incubated with SPRTNWT protein.
DNA fragments of 100-mer ssDNA or dsDNA were the most effi-
cient activators of SPRTN auto-cleavage activity.
In order to investigate if RJALS patient mutations are defective
with respect to their auto-cleavage activity, we tested the two
patient variants, SPRTNY117C and SPRTN-DC (Figures 3G–3I).
SPRTN-DC showed similar auto-cleavage activity to SPRTNWT,
whereas SPRTNY117C showed an80% reduction in auto-cleav-
age activity compared to SPRTNWT (Figure 3I). Considering that
SPRTNY117C binds DNA with similar affinity to SPRTNWT, we
conclude that its enzymatic deficiency is not due to defective
DNA binding. Our results suggest that SPRTNY117C directly af-
fects the protease active center (E112), which is located only
five amino acids upstream of the mutation. SPRTN-DC (1–246)
still retains auto-cleavage activity similar to SPRTNWT (Figures
3H and 3I) despite its lower DNA affinity (Figure 3A).
Trans-Cleavage Activity of SPRTN Metalloprotease
To address whether SPRTN auto-cleavage occurs in cis or in
trans, we incubated SPRTNWT with the enzymatic-dead variant
of SPRTN (SPRTNE112A). SPRTNWT cleaved SPRTNE112A (Fig-
ure S3E, compare lanes 2 and 4). These data suggest that
SPRTN cleaves itself in trans. To test the importance of DNA-
binding for trans-cleavage activity, we incubated two C-terminal
truncated variants of SPRTN that have medium (SPRTN1–268) or
low (SPRTN1–218) DNA affinity with SPRTNE112A (Figure 3A for
DNA affinity). SPRTN1–268 cleaved SPRTNE112A with similar effi-Figure 3. SPRTN Is a DNA-Dependent Metalloprotease with Auto-Prot
(A) Fluorescence polarization DNA binding assay of SPRTN and its C-terminally
(B) Schematic of in silico predicted DNA binding regions (green squares) in SPRT
(C) DNA binding affinity of SPRTNWT, SPRTNE112A, and SPRTNY117C toward ds,
(D) DNA induces auto-proteolysis of SPRTN. E112A mutation or 1,10 phenanthro
gels and visualized by Coomassie blue staining.
(E) WB illustrating SPRTN auto-cleavage.
(F) WB of total cell lysates after ectopic expression of FLAG-SPRTN (WT or E112A
activation of DNA damage signaling.
(G and H) In vitro enzymatic reactions as in (D), with patient mutations as indicat
(I) Quantification of auto-cleavage activity. Mean ± SD, n = 3.
See also Figure S3.
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contrast, SPRTN1–218 markedly lost trans-cleavage activity (Fig-
ure S3E, compare lane 4 to lane 8). Next, we asked if DNA is a
scaffold or an allosteric activator for SPRTN auto-cleavage activ-
ity. SPRTNWT auto-cleavage activity was maximal at equimolar
concentrations of protein and DNA in the reaction. Increasing
the concentration of DNA gradually inhibited SPRTN activity
(Figure S3F). Altogether, these results show that DNA serves
as a scaffold, which brings SPRTN and its substrate into prox-
imity, rather than acting as an allosteric activator. Loss of its
C-terminal DNA binding regions renders SPRTN unable to
perform its proteolytic activity, suggesting that auto-cleavage re-
duces the proteolytic activity of the cleaved forms.
Identification of SPRTN Substrates
We isolated DPCs from control and SPRTN-depleted HeLa cells
(Figure S4A) and analyzed them by label-free quantitative mass
spectrometry. Three independent experiments revealed 84
significantly increased (1.5-fold) proteins within the DPCs in
SPRTN-depleted cells, in comparison to control cells (Figure S4B
and Raw data repository: PRIDE). Although many of the identi-
fied substrates were DNA- and RNA-binding proteins, themajor-
ity were non-DNA binding proteins (Figure S4C). Given that any
protein in close vicinity to DNA can be crosslinked, especially nu-
clear matrix proteins, this is not a surprising finding. Accordingly,
non-DNA binding proteins such as Lamin B1 and DNA-PK are
enriched in DPCs isolated from D-SPRTN cells (Figure 5G).
We focused on histones andDNA topoisomerases, DNA-bind-
ing proteins with well-characterized cellular functions, which
emerged among the top hits (R1.98-fold increase) in our mass
spectrometry analysis (Figure S4D). To validate mass spectrom-
etry data, we analyzed specific DPCs, isolated as shown in Fig-
ure 1A, by slot-blot immunodetection. Depletion of SPRTN with
two different siRNAs significantly increased the amount of
Topo1, Topo2a, histone H3, and histone H4 (Figures 4A and
4B). To demonstrate that hyperaccumulation of Topo1 was spe-
cific to loss of SPRTN protease activity, we ectopically ex-
pressed SPRTNWT or SPRTNE112A in 30 UTR-targeted siRNA
SPRTN-depleted cells. Ectopic expression of SPRTNWT, but
not SPRTNE112A, rescued Topo1 accumulation (Topo1-cc) (Fig-
ure S4E). We further analyzed Topo1-ccs following treatment
with CPT (Figure 4C). Both SPRTN-depleted cells and patient
LCLs accumulate more Topo1-ccs compared with control cells,
thus further confirming the fundamental importance of SPRTN
protease activity in the removal of Topo1-ccs and protection
from DPC cytotoxicity (Figures S2B–S2H).eolytic Properties
truncated variants.
N protein and in SPRTN C-terminally truncated variants.
ss, and splayed DNA.
line (phen) inhibits SPRTN activity. The cleavage was analyzed on SDS-PAGE
) after FA treatment. The anti-phospho (P) Chk2 represents a positive control for
ed.
(legend on next page)
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Characterization of SPRTN Enzymatic Activity
To characterize the ability of SPRTN to cleave the identified sub-
strates, we performed in vitro cleavage activity assays using pu-
rified SPRTNWT protein. SPRTNWT cleaved all tested histones,
H2A, H2B, H3, and H4, in a DNA-dependant manner, but not
the cytosolic protein glutathione S-transferase (Figures 4D,
S5A, and S5B). Kinetic analysis of SPRTN auto-cleavage and
histone H3 cleavage in the same reaction revealed that SPRTN
cleaves H3 with slightly faster kinetics than itself (Figure 4E).
This suggests that SPRTN simultaneously cleaves substrates
and itself, but with a higher preference for the substrate. This
most probably leads to SPRTN inactivation as the cleaved
SPRTN products lose DNA binding affinity (Figure 3A), enzymatic
activity (Figure S3E), and have 2-fold lower substrate processiv-
ity kinetics (Figure 4F). This might be one of themechanisms, be-
side cell-cycle regulation (see below), by which SPRTN protease
self regulates to prevent deleterious and uncontrolled cleavage
in its vicinity.
We next tested the cleavage activity of various SPRTN
variants, focusing on histone H3 (Figures 4D and 4G). As ex-
pected, catalytically inactive SPRTNE112A did not cleave histone
H3. Similar to SPRTN auto-cleavage activity, patient variant
SPRTNY117C was severely affected with respect to histone H3
cleavage (8% active), whereas SPRTN-DC retained similar
activity to SPRTNWT. We extended the analysis of the cleavage
activity to two other identified substrates, Topo1 and Topo2a.
To this end, we purified YFP-Topo1 and GFP-Topo2a from
whole cell extracts under denaturing conditions and incubated
them with different variants of SPRTN. SPRTNWT, but not
SPRTNE112A, cleaved Topo1 and Topo2a in vitro, thus con-
firming Topo1 and Topo2a as SPRTN substrates (Figure 4G,
lanes 2 and 3). Characterization of patient mutations revealed
that SPRTNY117C was unable to cleave Topo1 and Topo2a. Un-
expectedly, in contrast to auto-cleavage (Figure 3H) and cleav-
age of histone H3 (Figures 4D and 4G), SPRTN-DC showed
severely reduced proteolysis of Topo1 and Topo2a in vitro,
similar to the smallest auto-cleaved form of SPRTN (1–227) (Fig-
ure 4G, lanes 5 and 6). These data show that SPRTN protease
cleaves various DNA-binding substrates in a DNA-dependent
manner. SPRTN protease activity is severely hampered by pa-
tient mutation Y117C for all tested substrates. Patient truncated
variant SPRTN-DC, although able to cleave itself and histone H3,
exhibits strongly reduced activity toward Topo1 and Topo2a,
suggesting that the C-terminal part of SPRTN is required for
optimal proteolysis of these substrates.Figure 4. Identification of SPRTN Substrates
(A) Slot-blots showing presence of Topo1, Topo2a, H3, and H4 DPCs after SPRTN
(B) DNA loading controls for DPC analysis, prior to benzonase treatment as in (A
(C) Slot-blots showing accumulation of Topo1-ccs after continuous CPT treatme
(D) WB and corresponding quantification showing that SPRTN cleaves histone H
(E) Time kinetics of H3 cleavage versus SPRTN self-cleavage within the same rea
time (min). Mean ± SD, n = 3.
(F) Comparison of time, response of H3 cleavage for SPRTNWT, and SPRTN-DC
(G) Histone H3, Topo1 and Topo2a are substrates of SPRTNprotease. The cleavag
image), Topo2a (middle image), or Topo1 (lower image). FL, full length.
(H) Multiple sequence alignment of histones’ cleavage products (CP) showing cle
cleavage products).
See also Figures S4 and S5.
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Next, we aimed to identify SPRTN protease cleavage sites and
asked if SPRTN protease cleaves at a specific amino acid
sequence motif. Cleavage products of H2A, H2B, H3, and H4
as well as auto-cleavage products of SPRTN were analyzed by
mass spectrometry to identify cleavage sites (Figures 4H and
S5C). We found that SPRTN cleaves histones H2A, H2B, H3,
and H4 within their unstructured, positively charged N-terminal
tail. All identified cleavage regions were enriched in arginine
and lysine residues and were in very close proximity to serine
residues in most cases. Analysis of SPRTN auto-cleavage sites
(CS) also showed an abundance of lysine, arginine, and serine
residues (CS 1 and 3), while specifically CS3 is heavily enriched
in serines (and, to a lesser extent, lysines and arginines) (Fig-
ure S3C). Similar to cleavage sites of histones, which are present
in disordered protein regions (N terminus), SPRTN cleaves itself
in multiple places in its C terminus, which is predominantly disor-
dered (Figure S5D). These results suggest that SPRTN is not a
sequence-specific protease, but cleaves unstructured protein
regions in the vicinity of lysine, arginine, and serine residues.
To test whether SPRTN also cleaves DPCs in vitro, we isolated
total DPCs by SDS/KCl precipitation assay and incubated them
with recombinant SPRTN. SPRTNWT, but not SPRTNE112A,
cleaves DPCs in vitro (Figure S6A). Thus far, our in vitro and
in vivo results suggest that SPRTN cleaves DNA-binding pro-
teins regardless of their DNA-binding status (i.e., covalent
DPCs or non-covalent). To further test this observation, we iso-
lated chromatin-bound Topo1 or Topo2 under denaturing condi-
tions from both untreated HEK293 cells and those treated with
CPT or ETO, respectively. SPRTN cleavage efficiency of immu-
nopurified Topo1 and Topo2a was similar between untreated
and Topo1/2a-cc enriched samples (CPT- and ETO-treated,
respectively; Figures S6B and S6C). Altogether, these data
suggest that SPRTN does not specifically cleave DPCs, but
DNA-binding substrates, and that SPRTN is indeed a pleiotropic
protease as it cleaves the majority of high-molecular weight
DPCs in vitro (Figure S6A, compare lanes 1 and 2).
SPRTN Removes DPCs during S-Phase and Protects
Proliferative Cells from DPC-Inducing Agents
Considering that SPRTN expression is absent in the G1-phase of
the cell cycle, and is rapidly upregulated as cells enter the
S-phase (Mosbech et al., 2012), we hypothesized that SPRTN
is involved in the removal of DPCs during DNA synthesis. Todepletion in HeLa cells and corresponding quantifications. Mean ± SEM, n = 3.
).
nt, as indicated, in D-SPRTN cells (left image) and RJALS LCLs (right image).
3 in the presence of DNA. Mean ± SD, n = 3.
ction mixtures expressed as increase in cleavage of either H3 or SPRTN over
as in (D). y axis was normalized to a 0%–100% scale. Mean ± SD, n = 3.
e products (*) were detected byWB using antibodies against histone H3 (upper
avage sites (arrow) in their unstructured N-terminal tails (* denotes alternative
(legend on next page)
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test this hypothesis, we analyzed the levels of DPCs during
S-phase progression in control and SPRTN-depleted cells. We
used T24 cells, which arrest in the G0 phase by contact inhibition
at 100% confluency and synchronously enter S-phase when
diluted to lower densities. Cells were arrested in G0, treated
with control-siRNA or SPRTN-siRNA for 2 days, and then diluted
to enter S-phase (Figure 5A). We monitored the total amount of
endogenous DPCs during S-phase progression. DPCs were
rapidly removed as control cells progressed through S-phase.
Conversely, SPRTN-depleted cells showed delayed kinetics of
DPC removal during S-phase progression (Figure 5B, compare
lanes 2 and 3 with 5 and 6). Western blot analysis of T24 cells re-
vealed that SPRTN is not expressed in G0 cells (Figure 5C),
further suggesting an essential role of SPRTN in protection
from DPCs during DNA synthesis. To investigate this hypothesis,
we treated G0-arrested or proliferative T24 cells with control or
SPRTN siRNA for 2 days, exposed the cells to a sub-lethal
dose of FA for an additional 2 days, and then monitored cell
viability (Figure 5D). Indeed, only SPRTN-depleted proliferative,
but not G0-arrested cells, were hypersensitive to FA (Figure 5E).
Furthermore, D-SPRTN HeLa cells hugely accumulate total
DPCs during S-phase progression compared to control cells
(Figure 5F). These data show that SPRTN processes DPCs dur-
ing S-phase progression, thus protecting cells from DPC
cytotoxicity.
SPRTN Is a Constitutive Part of the DNA Replication
Machinery
Having demonstrated that SPRTN protects proliferative human
cells from DPCs and knowing that patient mutation SPRTNY117C
is essential for unperturbed DNA replication fork progression
(Lessel et al., 2014), we asked whether SPRTN is a part of the
DNA replication machinery. We isolated SPRTN-SSH from total
HEK293 cell extracts over Streptactin sepharose under high salt
and detergent conditions to remove all unspecific binding pro-
teins from SPRTN-complexes in vivo. SPRTN co-precipitated
with the main components of the DNA replication machinery:
PCNA, minichromosome maintenance complex (MCM) subunits
2 and 6 and DNA polymerase d (Figure 6A). We next asked if
SPRTN is physically present at sites of DNA replication forks.
To address this question, we isolated proteins from nascent
DNA by iPOND technology. Similar to PCNA, MCM3, and DNA
polymerase d, SPRTN was present on nascent DNA (Figure 6B,
lane 2) and moved with the replisome as shown by thymidine
chase (Figure 6B, lane 3). Altogether, these data suggest that
SPRTN is part of the DNA replication machinery and moves
with the replisome during DNA synthesis.Figure 5. DPC Removal during S-Phase of the Cell Cycle
(A) Schematic of the experimental approach used to synchronize T24 cell in G0
(B) Total DPC levels in G0-, late G1-, and S-phase before and after SPRTN deplet
profiles were used as a control of S-phase entry.
(C) WB showing SPRTN expression or depletion in non-replicative and replicativ
(D) Schematic of cell viability measurement in replicative and non-replicative cel
(E) Cell viability of replicative and non-replicative T24 cells after SPRTN depletio
(F) Total DPC levels after G1/S release in HeLa WT and D-SPRTN cells visualized
used to control S-phase progression.
(G) WB showing presence of DNA-PK and Lamin B1 in DPCs in D-SPRTN HeLa
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We further asked whether SPRTN inactivation affects the pro-
gression of the DNA replication machinery. We isolated DNA
replication forks by iPOND and monitored their progression in
control and D-SPRTN HeLa cells (Figure 6C). Knock out of
SPRTN severely affected progression of DNA replication, as
shown by retention of PCNA and MCM3 on mature DNA (thymi-
dine chase, Figure 6C, compare lanes 3 and 4with lanes 6 and 7).
Defects in DNA replication fork progression in D-SPRTN cells
were demonstrated by DNA fiber assay (Figure S6D). Stalled
DNA replication forks inD-SPRTN cells accumulated Topo1 (Fig-
ure S6E), one of the substrates of SPRTN protease in vitro and
in vivo. These results indicate that SPRTN regulates replisome
progression and prevents accumulation of Topo1 at sites of
DNA replication forks. We further asked whether SPRTN physi-
cally interacts with Topos. To this end, we co-precipitated
SPRTN, as described earlier, and analyzed the presence of
Topo1 and Topo2a in the SPRTN complex. Co-immunoprecipi-
tation experiments revealed that SPRTN indeed forms a com-
plex with both Topo1 and Topo2a in vivo (Figure S6F).
To investigate how DPCs affect the progression of DNA repli-
cation, we employed the DNA fiber assay (Figure 6D). Treatment
of control cells with a low dose of FA or CPT caused a strong
reduction of DNA synthesis, detected as a decrease in DNA
replication fork velocity when the second nucleotide (IdU) was
incubated along with FA or CPT. Ectopic expression of
SPRTNWT rescued the DPC-induced DNA replication fork pro-
gression defect in both control and D-SPRTN cells (Figures 6D
and S6D). By measuring DNA replication fork velocity in RJALS
LCLs, we found that RJALS cells showed a stronger reduction
(2.5-fold) in DNA replication fork progression than control cells
when challenged with FA or CPT (Figure 6E). Altogether, these
results suggest that SPRTN is essential for the progression of
DNA replication forks challenged with DPC-inducing agents
and is a limiting factor in this process since reduced fork speed
in FA/CPT-treated control or D-SPRTN cells can be rescued by
SPRTNWT overexpression.
SPRTN Prevents DPC-Induced DSBs in the S-Phase
We hypothesized that the decreased velocity of DNA replication
forks in SPRTN-depleted or RJALS cells in the presence of DPC-
inducing agents leads to prolonged stalling of replisomes and
consequently to DNA replication fork collapse, visualized as
DNA ds breaks (DSBs), a phenotype observed in RJALS patients
(Lessel et al., 2014). We continuously exposed control or
D-SPRTN cells to mild doses of FA or CPT and monitored theand monitor DPC levels during S-phase entry.
ion in HeLa cells visualized by silver staining. The WB of cyclin A and cell-cycle
e T24 cells.
ls.
n and FA treatment.
by silver staining. The WB of cyclins and cell-cycle profiles (lower images) were
cells after G1/S release. Whole cell extract: WCE. Mean ± SEM, n = 3.
(legend on next page)
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formation of 53BP1 foci, a recognized marker for DSBs, over a
period of 6 hr by immunofluorescence microscopy in fixed cells.
Cyclin A staining was used as a marker for S-/G2-phase-positive
cells. The formation of 53BP1 foci was induced in both cyclin A
positive and negative cells after FA or CPT treatment, further
confirming DPC-induced genotoxicity (Figures 6F and S6G–
S6I). However, the average number of 53BP1 foci per cell was
2- to 3-fold increased after FA or CPT treatment in cyclin A-pos-
itive D-SPRTN HeLa cells compared to control HeLa cells (Fig-
ures 6F and S6G). In contrast, the number of 53BP1 foci in cyclin
A-negative cells was the same in both D-SPRTN and control
cells (Figures S6H and S6I). These results suggest that SPRTN
prevents DPC-induced DSBs during DNA synthesis.
DISCUSSION
We have revealed mechanistic insights into SPRTN protease ac-
tivity for DPC repair and established SPRTN as a DNA replica-
tion-coupled protease (Figure 7). Our work identifies the missing
protease involved in DNA replication and in the processing of
Topoisomerase 1 and 2 crosslinks (Ashour et al., 2015; Duxin
et al., 2014; Gao et al., 2014; Interthal and Champoux, 2011).
Biochemical characterization of SPRTN mutations from RJALS
patients shows that RJALS is caused by a defect in SPRTN pro-
tease activity, rendering it unable to process DPCs during DNA
replication and therefore leading to DNA replication stress, one
of the main causes of genome instability and cancer.
DNA Replication-Coupled SPRTN Proteolysis
Our finding is in agreement with recent biochemical data in Xen-
opus egg extract, showing that DNA replication-coupled proteol-
ysis is essential for DPC removal (Duxin et al., 2014), a model
proposed by the Sancar laboratory (Reardon et al., 2006). How-
ever, the enzyme for this pathway remained unknown until now,
when we show that SPRTN is an active protease and constitutive
part of the replisome. Taking into consideration that DPCs are
ubiquitous and that virtually any protein present in close prox-
imity to DNA can be crosslinked, the proteolytic activity of
SPRTN in DNA replication is essential. Cell-cycle dynamics of
SPRTN expression support our hypothesis, with SPRTN being
absent in G0 of T24-cells, and emerging upon entry into
S-phase. This is in agreement with published data, showing
that the level of SPRTN is downregulated in cells in G1 phase
by the E3-ubiquitin ligase APC-complex and upregulated as
cells enter S-phase (Mosbech et al., 2012). We therefore pro-Figure 6. SPRTN Is a Part of the DNA Replication Machinery and Regu
(A) CoIP of SPRTN-Strep-Strep-His (SSH) from Flp-In HEK293 cells stably expres
(B) Schematic of the iPOND approach (upper image). iPOND is illustrating that SPR
label nascent DNA (lane 2) and then chased with thymidine where indicated (ma
(C) iPOND showing increased retention of replisome proteins on mature DNA in
(D) DNA fiber assay in HeLa cells after overexpression of FLAG-SPRTNWT or emp
quantification of IdU-labeled tract length in the presence of DPC-inducing agents
tract length in kilobases.
(E) DNA fiber assay in RJALS LCLs (B-II:1) and control LCLs after FA or CPT trea
(F) Quantification of 53BP1 foci in cyclin A positive HeLaWTorD-SPRTN cells afte
to untreated cells (time point 0) (upper image). The representative micrographs of
image). Mean ± SEM, n = 3.
See also Figure S6.
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in proliferative cells. We cannot exclude a potential role for
SPRTN in non-proliferative cells, but if it exists, this function is
not associated with DNA replication-coupled DPC repair.
DNA-Protein Crosslink Repair
Our work addresses an emerging question in the field of DNA
repair: how are DPCs removed from chromatin? Despite the
frequent occurrence of DPCs, we poorly understand the process
of DPC repair (Ide et al., 2015). It is believed that DPC repair
partially depends on two canonical DNA repair pathways, NER
and HR (Barker et al., 2005; Nakano et al., 2007). However,
both repair pathways are limited by the fact that NER can only
act on smaller protein crosslinks, not larger than 11 kDa, and
HR relies on DSB formation that leads to recombinogenic events
and associated genomic instability. As a consequence, other
repair mechanisms should be involved in DPC processing and
maintenance of genomic stability. Indeed, DPC accumulation
is neither observed upon inactivation of key NER and HR players
nor the Fanconi anemia pathway (Figure S2A), suggesting that
the SPRTN-dependent DPC repair pathway is the main, special-
ized pathway for DPC repair in human cells. Early embryonic
lethality of SPRTN knockout mice (Maskey et al., 2014), and
the identification of SPRTN as one of the essential genes in the
human genome (Hart et al., 2015; Wang et al., 2015), further sup-
ports the conclusion that SPRTN is a critical component of the
unique DNA repair system, namely, DPC repair pathway.
Characterization of RJALS Patient Mutations
We demonstrated that the protease activity of patient mutation
SPRTNY117C is severely affected on all tested substrates. The
reason why the Y117Cmutation affects SPRTN enzymatic activ-
ity is not clear. Sequence comparisons show that this residue is
not strictly conserved among SPRTN homologs (Figure S7A),
although it is commonly hydrophobic, even among the wider zin-
cin family. The close proximity of Y117 to the catalytic center,
located only two residues downstream of the second potential
Zn-binding histidine (H115), and the non-conservative nature of
the substitution indicate that the variant may be unable to form
the active site with the correct geometry. This is possibly a result
of steric effects involving the positioning of the end of the
HEXXH-containing helix and the subsequent loop containing
the third potential Zn2+ ligand.
The other pathogenic mutation, SPRTN-DC, is proteolytically
active toward itself (auto-cleavage) and histones (Figures 3Hlates DNA Replication Fork Progression
sing SPRTN upon Dox induction showing association with replisome proteins.
TNmoveswith the replisome. HEK293 cells were treatedwith EdU for 10min to
ture DNA, lane 3).
D-SPRTN HeLa cells (lane 6 and 7).
ty FLAG-vector. The representative DNA fibers are shown (upper image). The
(50 mM FA, 25 nM CPT) is shown. The numbers (in green) are mean values of
tment performed as in (D).
r FA treatment (50 mM). The data represent fold-change in 53BP1 foci compared
53BP1 foci in Cyclin A positive cell at 6 hr after FA treatment are shown (lower
Figure 7. Model of DNA Replication-Coupled DPC Repair
SPRTN is a constitutive part of the replisome and cleaves DPCs during repli-
cation fork progression. SPRTN protease protects proliferative cells from
DPC-induced cytotoxicity (left). SPRTN deficiency (SPRTN mutations in
RJALS, SPRTN haploinsufficient mice) causes stalling of the DNA replication
fork due to pathological accumulation of DPCs, which in turn leads to DSBs
and genomic instability (right).and 4D), but is severely impaired in processing Topo1 and
Topo2a (Figure 4G). The sensitivity of SPRTN-depleted cells
to CPT could not be completely restored by SPRTN-DC, sug-
gesting that this patient mutation, although proteolytically
active, cannot properly process certain substrates, such as
Topo1 and Topo2. One reason could be that the C-terminal
part is important for binding particular substrates and is
involved in SPRTN substrate specificity. The increased levels
of DPCs in RJALS patient cells, and the inability of DNA repli-
cation in RJALS cells to cope with the induction of non-enzy-
matic (FA) or enzymatic (CPT) DPCs, demonstrates that DPCs
such as Topo1 and Topo2a, and most probably many others,
are the main cause of RJALS syndrome. We propose thatRJALS is a human disease linked to defective DPC repair
pathway.
Comparison between SPRTN and Wss1
Bioinformatic analysis suggests that SPRTN and Wss1 have a
common ancestor (Stingele et al., 2015). While it is true that
both enzymes are distantly related to the zinc metalloprotease
superfamily, the two sequences can only be aligned over a rela-
tively short 95 amino acid (aa) residue region with 24% sequence
identity (comparing the human and S. cerevisiae enzymes) (Fig-
ure S7B). This common region includes the conserved HEXXH
motif, shared among a wider set of enzymes with diverse func-
tions, which provides the platform for Zn2+ binding via two histi-
dines, with a neighboring glutamate residue thought to play a
role in catalysis (Hooper, 1994). Beside this common core, no
other regions of sequence similarity could be found. Wss1 and
SPRTN show similar enzymatic properties, but their cellular
function is partially uncoupled. SPRTN interacts with DNA repli-
cation machinery and binds ubiquitinated substrates via its Ub-
binding domains, while Wss1 binds and processes SUMOylated
substrates via its SUMO-interacting motifs (Balakirev et al.,
2015). Inactivation of SPRTN causes a massive accumulation
of total DPCs in proliferative human cells, including Topo1,
Topo2a, and histones. In contrast, yeast cells lacking Wss1 do
not accumulate total DPCs and do not show hypersensitivity to
CPT (Stingele et al., 2014).
EXPERIMENTAL PROCEDURES
DNA-Protein Crosslinks Isolation
DPCswere detected using amodified rapid approach to DNA adduct recovery
(RADAR) assay (Kiianitsa and Maizels, 2013). The patient material used in this
study (LCLs) was approved by the Human Research Ethics Committee of the
Royal Children’s Hospital and the Oxford Research Ethics Committee Oxford
Radcliffe Biobank (Ref.: 15/A156), University of Oxford. See the Supplemental
Experimental Procedures for details.
DNA-Protein Crosslinks Detection
Specific DPCs were detected using a vacuum slot-blot manifold (Bio-Rad)
followed by immunodetection. DPCs were visualized using the Bio-Rad
ChemiDoc XRS Plus Analyzer. See the Supplemental Experimental Proced-
ures for details.
Protein Purification
For overexpression in E. coli cells, SPRTN constructs were cloned in to either
the pNIC-ZB vector (full-length SPRTN-WT, SPRTN-E112A, and SPRTN-
Y117C), or pNIC28-Bsa4 vector (all other truncated constructs). For purifica-
tion of full-length constructs containing a TEV cleavable Z-basic-his tag, cells
lysates were applied to a Ni-sepharose IMAC gravity flow column. Elution frac-
tions were applied directly to a 5 mL HiTrap SP HP column, washed, and
eluted. The purification tag was cleaved with the addition of 1:20 mass ratio
of His-tagged TEV protease during overnight dialysis. Protein identities were
verified by LC/ESI-TOF mass spectrometry. See the Supplemental Experi-
mental Procedures for details.
Fluorescence Polarization DNA Binding Assays and DNA Probe
Annealing
See the Supplemental Experimental Procedures for details.
Generation of CRISPR/Cas9 SPRTN Partial Knockout HeLa Cells
See the Supplemental Experimental Procedures for details.Molecular Cell 64, 704–719, November 17, 2016 717
SPRTN Substrate Cleavage Assay
SPRTN enzymatic reactions were performed in 150 mM NaCl and 25 mM Tris
(pH 7.4) in a PCR block at 37C. The reaction volume was typically 10 mL and
contained: E. coli purified recombinant SPRTN (1–10 mg/mL solution), sub-
strate (typically 1 mg/mL solution), and 100 bp dsDNA oligonucleotide probe.
See the Supplemental Experimental Procedures for details.
Isolation of Proteins On Nascent DNA
See the Supplemental Experimental Procedures for details.
DNA Fiber Assay
The DNA fiber assay was performed as described previously (Lessel et al.,
2014). See the Supplemental Experimental Procedures for details.
Mass Spectrometry Analysis
See the Supplemental Experimental Procedures for details.
Quantitative Proteomics and Data Analysis
See the Supplemental Experimental Procedures for details.
Statistical Analysis
See the Supplemental Experimental Procedures for details.
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SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
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  SUPPLEMENTRY FIGURE LEGENDS  
Figure S1. SPRTN prevents accumulation of DNA-protein crosslinks (DPCs). Related to Figure 
1. (A) Total DPCs isolated from HEK293T cells (lane 1), and after benzonase (30 min, lane 2) or 
proteinase K digestion (3h, lane 3) at 55˚C, resolved with SDS-PAGE and visualised using silver 
staining. (B) Analysis of enzymatic DPCs by slot-blot; Top1-ccs after CPT treatment (upper panel) 
and Top2-ccs after ETO treatment (lower panel). dsDNA as a loading control for DPC isolates before 
benzonase treatment (C) Depletion of SPRTN in HeLa cells with three different siRNAs causes 
accumulation of total DPCs. Total amount of DPCs was quantified and expressed as a fold change (n 
= 3). Corresponding cell cycle profiles for each sample (PI; propidium iodide). WCE; whole cell 
extract. (D) Depletion of SPRTN in HEK293 cells with three different siRNAs leads to a significant 
accumulation of total DPCs as in C. Total amount of DPCs was quantified and expressed as a fold 
change (n = 3). WCE; whole cell extract.  Cell cycle progression was monitored by propidium iodide 
(PI) (right panels). (E) Schematics of CRISPR/Cas9 SPRTN partial knock-out in HeLa cells (Δ-
SPRTN). The sgRNA sequence targeted the first exon of SPRTN. (F) CRISPR partial knock-out was 
confirmed by western blot with α-SPRTN antibody. (G) Confirmation of SPRTN partial knock-out in 
HeLa cells by genomic DNA sequencing. Ten parental and 25 CRISPR clones were sequenced. The 
CRISPR/Cas9 plasmid induced either a 1bp deletion or 1bp insertion, leading to a frameshift and 
introduction of a premature stop codon. Out of 25 CRISPR clones, 17 were altered while the rest 
remained unchanged indicating partial knock-out of SPRTN (sequences from 10 clones that show a 
representative distribution of mutations are shown).  
Figure S2. SPRTN protects cells from the DPC-inducing agents and acts independently of HR, 
NER, and Fanconi Anemia pathways in DPC removal. Related to Figure 2. (A) Total DPC levels 
after depletion of SPRTN, XPC, MRE11 or FANCD2 in HeLa cells visualised by silver staining with 
corresponding slot blots showing equal amount of DNA used for DPC analysis and Western blots for 
depletion efficiencies. WCE; whole cell extract. Corresponding quantification of DPC levels 
expressed as a fold change to DPCs levels in HeLa WT cells and cell cycle profiles (PI, propidium 
iodide) (right panel). (B) Clonogenic survival assays of siRNA control (CTR) or siRNA SPRTN-
depleted HeLa cells treated with CPT for 24 hrs. Colonies were analysed after 7 days by automated 
cell counter (n = 3). (C - F) Cell survival of SPRTN depleted Flp-In HeLa cells after doxycycline-
induced expression of SPRTNWT (C), SPRTNE112A (D), SPRTNY117C (E), or SPRTN-ΔC (F) following 
CPT treatment. (G) Cell survival after SPRTN and Topo1 co-depletion following CPT treatment with 
corresponding WB to monitor depletion efficiency (lower panel). (H) Cell survival after SPRTN and 
TDP1 co-depletion following CPT treatment with corresponding WB showing depletion efficiencies 
(lower panel). (I) Cell survival after SPRTN and FANCD2 co-depletion following FA (upper panel) 
or CPT (lower panel) treatment with corresponding WB showing depletion efficiencies (right panel). 
	  Figure S3. SPRTN is a zinc and DNA-dependent protease. Related to Figure 3. (A) Comparison 
of denaturing (shown in red) and native (shown in black) mass spectra for wild type and E112A 
SPRTN constructs (SPRTN 1-268 amino acid long truncated variant to avoid Zn-binding UBZ-
domain). (B) Schematic of the SPRTN protein sequence showing the active site HEXXH (in red), p97 
interacting SHP domain, PCNA binding domain (PIP box) and UBZ domain. In silico predicted DNA 
binding residues are shown in green. Four or more consecutive residues with DNA binding capacity 
are enclosed in green squares. (C) Identification of SPRTN self-cleavage sites. Self-cleavage sites of 
the SPRTN protease were identified by mass spectrometry analysis. Only cleavage sites (CS) which 
could be determined with high confidence (unique peptide matches, ppm = 100) are shown (CS 1-3) 
(See also Figure S7C). (D) Characterization of SPRTN auto-cleavage activity. In vitro enzymatic 
reactions were performed for 2 hours at 37˚C with purified SPRTNWT and DNA probes of different 
lengths and visualized on gels by Coomassie Blue staining. (E) SPRTN self-cleavage occurs in trans. 
The enzymatic dead protein SPRTNE112A was incubated with the full length or different C-terminal 
truncations of the SPRTNWT protein for 2 hours at 37˚C. Trans-cleavage of SPRTNE112A was 
quantified and expressed as a percentage of cleavage (n = 3), left panel. (F) Titration of the optimal 
DNA concentration to induce SPRTN self-cleavage. In vitro enzymatic reactions were performed with 
increasing concentrations of dsDNA (100mer) for 2 hours at 37˚C.  
Figure S4. Quantitative mass spectrometry analysis of DNA-protein crosslinks in SPRTN-
depleted cells. Related to Figure 4. (A) Total DPCs were isolated in triplicate from siRNA control 
(CTR) or siRNA SPRTN-depleted (siSPRTN#1) HeLa cells according to the RADAR protocol and 
were visualized by silver staining on SDS-PAGE gels. Samples were processed for mass spectrometry 
analysis. (B) Abundance profile of the 114 proteins significantly increased (p-ANOVA <0.05) in 
siSPRTN#1 as compared to control (n = 3 biological replicates). Proteins selected were identified and 
label-free quantified with at least two unique peptides using Progenesis IQP software. (C) Pie chart 
showing protein function classification of the 114 significantly overexpressed proteins in siSPRTN#1, 
which was performed using PANTHER Classification System (Protein ANalysis THrough 
Evolutionary Relationships, version 10.0). Proteins were identified and quantified with at least two 
unique peptides. (D) Increased DNA topoisomerase 1, Histone H4 and Histone H2B association to 
DNA in SPRTN#1 depleted cells. Normalised abundance of three proteins differentially increased in 
siSPRTN#1 depleted cells as compared to control (fold change ≥ 1.5; p-ANOVA <0.05). (E) Total 
DPCs were isolated by the RADAR protocol as in Figure 1A from stable Flip/In HeLa cell lines 
depleted for endogenous SPRTN by 3’ UTR siRNA.  Ectopic expression of SPRTNWT or SPRTNE112A 
was induced by DOX and Topo1 levels in DPCs were analyzed by slot blot using a specific antibody 
against Topo1. Equal amount of DNA was loaded and confirmed by slot blot followed by immune-
detection against dsDNA (lower panel). Total amount of Topo1 was quantified and expressed as a 
fold change compared to siCTR cells (n = 3, right panel). 
	  Figure S5. SPRTN cleaves histones H2A, H2B and H4. Related to Figure 4. (A) SPRTNWT 
cleaves core histones in vitro. Enzymatic reactions were performed with purified SPRTN proteins as 
indicated and different histones in the presence of dsDNA for 8 hrs at 37˚C. Proteolytic activity was 
monitored by Western blot using antibodies against the specific histones. (B) Cytosolic protein 
glutathione S-transferase (GST) is not cleaved by SPRTN. Enzymatic reactions were performed as 
described above. (C) Mass spectrometry analysis of histones H2A, H2B, H3 and H4 cleavage 
products (CP) after SPRTN proteolysis. * denotes unspecific peaks. Peaks that are not labelled as CP 
had more than one unique peptide hit, thus making it impossible to determine exact cleavage site (see 
Methods) (D) Disorder propensity plot for human SPRTN with the known domain boundaries 
overlaid. Values greater than 0.5 are considered to be likely disordered.  
Figure S6. SPRTN cleaves Topo1-ccs, Topo2α-ccs, and DPCs of high molecular weight and 
prevents protein accumulation at the replisome and DSB formation. Related to Figure 6. (A) 
Left gel:  In vitro enzymatic reactions of SPRTN cleavage of DPCs. Incubation of DPCs isolated from 
HeLa cells with SPRTNWT, but not SPRTNE112A, leads to a reduction of high molecular weight 
(h.m.w.) DPCs, and DPCs above 100 kDa (lane 2 in comparison to lanes 1 and 3). Right gel: analysis 
of SPRTN WT or E112A on SDS-PAGE/Silver staining to demonstrate that products in lanes 2 and 3 
are coming from recombinant SPRTN in the reaction. (B) SPRTN cleaves Topo1 and Topo1-ccs with 
similar efficiency. Topo1 or Topo1-ccs (+CPT) were immunoprecipitated under denaturing conditions 
from chromatin fraction of HEK293T cells before or after CPT treatment and in vitro enzymatic 
reactions were performed as in Figure 4F. (C) SPRTN cleaves Topo2α and Topo2α-ccs (+ETO) with 
similar efficiency. Topo2α and Topo2α-ccs were immunoprecipitated under denaturing conditions 
from chromatin fraction of HEK293T cells before or after ETO treatment and in vitro enzymatic 
reactions were performed as in Figure 4F. (D) Ectopic expression of SPRTNWT rescues DNA 
replication fork velocity in Δ-SPRTN cells before and after FA treatment (n = 3). Numbers in green 
indicates mean value of DNA synthesis in kilobases (E) Topo1 protein levels increase at the replisome 
in Δ-SPRTN cells. iPOND was performed as in Figure 6B. (F) SPRTN forms a complex with Topo1 
and Topo2α in vivo. Co-IP of SPRTN-SSH tag was performed upon doxycycline induction of 
SPRTNWT expression in Flp-In 293 cells using StrepTactin beads. (G) Graphic representation of the 
fold-change in the average 53BP1 foci following treatment with camptothecin (25 nM) in HeLa WT 
or Δ-SPRTN cells. DSB formation was monitored in cyclin A positive cells, as described in Figure 
6F. (H and I) Graphic representation of the fold-change in the average 53BP1 foci following treatment 
with FA (50 µM, H) or CPT (25 nM, I), respectively in HeLa WT or Δ -SPRTN negative for cyclin A.  
Figure S7. SPRTN protein alignment and mass spectrometry analysis of SPRTN auto-cleavage 
(A) Multiple sequence alignment of SPRTN homologues from a diverse set of multicellular 
eukaryotes. Regions with dense clusters of strictly conserved residues, which also contain possible 
consensus motifs for metal binding, are numbered and highlighted in green (I-VII). (B) Pairwise 
	  sequence alignment of human SPRTN and S. cerevisiae WSS1 shows low similarities over a short 
region of the catalytic domain around the HEXXH motif, underlined in black. (C) Mass spectrometry 
analysis of full length SPRTN-WT auto-cleavage products (CP) identified at least five cleaved 
products within the C-terminal region of SPRTN. 
 
	  EXTENDED EXPERIMENTAL PROCEDURES 
 
Chemicals, plasmids and recombinant proteins 
Formaldehyde (FA), Camptothecin (CPT), Etoposide (Eto), methylglyoxal, hygromycin, puromycin, 
5-Chloro-2′ deoxyuridine (CldU) and 5-Iodo-2′-deoxyuridine (IdU) were purchased from Sigma-
Aldrich. Topo1/YFP and Topo2α/GFP plasmid constructs were a kind gift from Prof Sherif El-
Khamisy. pcDNA3.1/Flag (Invitrogen) and pCDNA5/FRT/TO-cSSH (Invitrogen) were used in the 
mammalian expression system and pNIC-ZB vector and pNIC28-Bsa4 were used in the E.coli 
expression system. 
 
Antibodies 
The following primary antibodies were used in this study: anti-SPRTN (rabbit, polyclonal) raised 
against the N-terminal part (1–240 aa) of SPRTN (home made, dilution 1:1000); anti-SPRTN raised 
against the C-terminal part of SPRTN (Atlas HPA 025073, dilution 1:1000); anti-Topoisomerase 1 
(Bethyl A302-589A, dilution 1:5000); anti–topoisomerase 2α (Bethyl A300-054A, dilution 1:10000); 
anti-dsDNA (Abcam ab27156, dilution 1:5000); anti-histone 2A (Cell signalling 2578, dilution 
1:1000); anti-histone 2B (Cell signalling 2934, dilution 1:1000); anti-histone 3 (Abcam ab1791, 
dilution 1:1000); anti-histone 4 (dilution 1:1000); anti-PCNA (Abcam ab29, dilution 1:1000); anti-
MCM6 (Santa Cruz sc-9843, dilution 1:1000); anti-MCM2 (Cell signalling 4007, dilution 1:1000); 
anti-Polδ (Abcam ab10362, dilution 1:1000); anti-βActin (abcam ab6276, dilution 1:1000); anti-
Lamin B1 (ThermoFisher Scientific PA5-19468, dilution 1:1000); anti-cyclin A (Santa Cruz sc751, 
dilution 1:1000); anti-cyclin B1 (BD Biosciences 610219, dilution 1:1000); anti-cyclin E (Millipore 
05-363, dilution 1:1000); anti-DNA-PK (Cell signalling 12311S, dilution 1:1000) and anti-rat and 
anti-mouse 5-bromo-2′-deoxyuridine (BrdU) (anti mouse Abcam ab6326, dilution 1:500, and anti rat 
BD Biosciences 347580, dilution 1:100, respectively). Secondary antibodies used in this study are as 
follows: anti-mouse horseradish peroxidase (HRP) (Sigma A2304, dilution 1:50000); anti-rabbit HRP 
(Sigma A05451, dilution 1:50000); Anti-rat Cy3 (Jackson ImmunoResearch 712-116-153, dilution 
1:300) and anti-mouse Alexa-488 (Molecular Probes A11001, dilution 1:300). 
 
Cloning and site directed mutagenesis 
The I.M.A.G.E. full-length SPRTN cDNA clone (IRATp970E1156D, ImaGenes) was cloned into 
pcDNA3.1 (containing the Flag-tag at the N-terminus) and pCDNA5/FRT/TO-cSSH vector 
(containing Strep and HA tags at the C-terminus) for expression in a mammalian system. For 
expression in E. coli, SPRTN cDNA clone was cloned into pNIC-ZB vector with N-terminal His and 
ZB tags (full length SPRTNWT, SPRTNE112A, and SPRTNY117C) or pNIC28-Bsa4 vector with N-
terminal His tag (all other truncated constructs). Site-directed mutagenesis was performed using 
	  mutagenic primers by PCR using AccuPrime Pfx DNA polymerase (Invitrogen) according to the 
manufacturer instructions. DNA sequence was verified by Source Biosciences sequencing service, 
Oxford, UK.  
 
Mammalian cells, siRNA and transfection protocols 
HeLa, HEK293T and T24 cells were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal 
calf serum. Epstein-Barr virus (EBV)-transformed LCLs were cultured in RPMI medium with 15% 
fetal calf serum. Cells were grown to 50–80% confluence before treatment with CPT, ETO, FA or 
methylglyoxal at indicated concentrations. siRNA transfections were performed using Lipofectamine 
RNAiMax reagent (Invitrogen) according to the manufacturer’s protocol, and depletion was assayed 
at 72 h post-transfection. siRNA sequences are as follows:  
siSPRTN#1 (GUCAGGAAGUUCUGGUUAA); 
 siSPRTN#2 (CACGAUGAGGUGGAUGAGUAU);  
siSPRTN#3 (AGCCAAUAUAACGGUAUACCA);  
siTopo1 (GGUCCCUGUUGAGAAACGA);  
siTDP1 (GGAUAUUGCGUUUGGAACA);  
siMre11 (GAUAGACAUUAGUCCGGUU) 
siXPC (SMARTpool, 40nM) (Dharmacon), and 
 siFANCD2 (SMARTpool, 40nM) (Dharmacon). 
Plasmid transfections were performed using FuGene HD reagent (Promega) according to the 
manufacturer’s protocol, and drug response was assayed at 24-48 h post-transfection. For denaturing 
immunoprecipitation (IP) of Topo1/YFP and Topo2α/GFP, HEK293T cells were transfected with 
corresponding recombinant plasmid using polyethyleneimine (PEI) reagent (Tom et al., 2008) and 
collected for IP after 48h. 
 
Generation of SPRTN/Flp-In T-REx stable cell lines  
HeLa and HEK-293 SPRTN/Flp-In T-REx stable cell lines were prepared according to 
manufacturer’s protocol for doxycycline inducible constitutive expression of SPRTN variants (WT, 
E112A, Y117C and DC). The SPRTN cDNA was amplified by PCR and cloned in 
pCDNA5/FRT/TO-cSSH vector (containing Strep and HA tags at C-terminal) using BamH1 and Not1 
restriction sites to generate DVC1-WT-FRT/TO construct. The construct was used as a template to 
generate the E112A, Y117C and DC variants by site directed mutagenesis. The DVC1-wt and DVC1-
mutation-FRT/TO constructs were transfected with pOG44 vector into Flip-In host cell lines for site-
specific integration in genome. The transformed cells were selected under hygromycin B to generate 
DVC1-Flp-In T-REx stable cell lines. The expression of DVC1 was confirmed by doxycycline 
induction (1µg/ml) followed by western blot analysis. 
 
	  Generation of Crispr/Cas9 SPRTN partial knock-out HeLa cells (Δ-SPRTN) 
The CRISPR plasmid was obtained from the Genome Engineering Oxford (GEO) centre, Sir William 
Dunn School of Pathology, Oxford, UK. The donor plasmid (pX459v2), containing the sgRNA, Cas9 
and puromycin resistance marker, was transfected into HeLa cells using Fugene HD (Promega). The 
sgRNA sequence (CACGCTCCACTTCACCTCGACGG) targeted the first exon of SPRTN. 24h after 
transfection, cells were selected with 0.6 µg/ml puromycin for 72h and then seeded as single cells in a 
96-well plate (one cell/well) in order to generate a population of cells derived from a single clone (i.e. 
a genetically homogenous population of cells). In parallel, 40 distinct CRISPR-targeted HeLa cell 
clones (each grown from a single cell) were tested for SPRTN protein expression by Western blotting. 
Only those HeLa clones, which showed a reduction in SPRTN protein levels, were selected for 
sequencing. Genomic DNA was isolated from each individual pool of genetically-homogenous HeLa 
cells and the region containing the SPRTN sgRNA target site was amplified by PCR and subcloned 
into Topo vectors to achieve allele separation and transformed into bacteria. Plasmid was then isolated 
from 25 bacterial colonies and sequenced. The clones in Figure S1 refer to plasmids isolated from 
individual bacterial colonies derived from HeLa cells grown from a single clone. 70% (i.e. 17/25 or 
2/3) of the sequences showed Cas9-mediated mutations in exon 1 of SPRTN. Knowing that HeLa cells 
(cancer cell line) have three copies of chromosome 1, where the SPRTN gene is located, this result 
suggests that 2 out of 3 alleles of the SPRTN gene have been knocked-out. Therefore we called our 
SPRTN-knock out cells “partial knock-out” as 2 alleles are knocked-out and 1 allele is still present. 
 
Western Blot (WB) 
Standard protocols for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS PAGE) and 
immunoblotting were used (Henderson and Wolf, 1992). Nitrocellulose membrane (GEHealthcare) or 
PVDF (BioRad) were used to transfer proteins from polyacrylamide gels depending on the antibody.  
 
DNA-protein crosslinks isolation 
DPCs were detected using a modified rapid approach to DNA adduct recovery (RADAR) assay 
(Kiianitsa and Maizels, 2013). In brief, 1.5 to 2 x 106 cells were lysed in 1 ml of M buffer (MB), 
containing 6 M GTC, 10 mM Tris–HCl (pH 6.8), 20 mM EDTA, 4% Triton X100, 1% Sarkosyl and 
1% dithiothreitol. DNA was precipitated by adding 1 ml of 100% ethanol and was washed three times 
in wash buffer (20 mM Tris–HCl pH 6.8, 150 mM NaCl and 50% ethanol) and DNA was solubilized 
in 1 ml of 8 mM NaOH. A small aliquot of the recovered DNA was digested with 50 µg/ml proteinase 
K (Invitrogen) for 3 hours at 50°C and quantified using PicoGreen dye (Invitrogen) according to 
manufacturer instructions to determine DNA concentration. DNA concentration was further 
confirmed by slot-blot analysis followed by immunodetection with antibody against dsDNA. 
As confirmation of results obtained by RADAR assay for DPC isolation, DPCs were isolated using 
	  KCl/SDS precipitation assay (Zhitkovich and Costa, 1992). In brief, approximately 2x106 cells were 
lysed in 1 ml denaturing lysis buffer (2 % SDS, 20 mM Tris/HCl pH 7.5) followed by sonication (5 
cycles, 20 sec). Proteins were then precipitated in buffer containing 200 mM KCl, 20 mM Tris, pH 
7.5 (assay buffer) and incubated on ice for 5 min. The precipitate was pelleted by centrifugation at 
4°C (15,000g, 5min). Supernatant was used for quantifying soluble DNA. The pellet was resuspended 
in 1ml assay buffer and incubated at 55°C for 5 min, cooled on ice for 5 min, and precipitated by 
centrifugation (15,000g, 5min). Pellet was washed three times in assay buffer prior to final 
resuspension in 500 µl of assay buffer. Proteins were digested with 0.2 mg/ml Proteinase K (55°C, 3 
hours). Samples were cooled on ice for 5 min then centrifuged. The final supernatant contained the 
crosslinked DNA. Soluble and crosslinked DNA were quantified by PicoGreen. The amount of DPCs 
was calculated as the ratio between DNA precipitated by SDS/KCl and total DNA (SDS/KCl 
precipitated plus soluble DNA). 
DNA-protein crosslinks detection  
Total DPCs were visualized by silver staining (Sigma) as recommended by the manufacturer after 
electrophoretic separation on polyacrylamide gels. DNA was digested with benzonase (Invitrogen) for 
30 minutes at 37°C. Proteins were precipitated by standard Trichloroacetic Acid (TCA) protocol 
(Link and LaBaer, 2011) and resolved by SDS-PAGE gel. Specific DPCs were detected using a 
vacuum slot-blot manifold (Bio-Rad) followed by immunodetection. In brief, equal amounts of DNA 
were diluted in Tris-buffered saline (TBS) and applied to either a polyvinylidene difluoride (PVDF, 
Millipore) or nitrocellulose (Bio-Rad, Hercules CA) membrane using a vacuum slot-blot manifold. 
The membrane was then blocked in 3%BSA in TBST (TBS containing 0.1% Tween 20), incubated 
with primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary 
antibodies. DPCs were visualized using the Bio-Rad ChemiDoc XRS Plus Analyzer. Sample loading 
was further confirmed by slot-blot detection of dsDNA with a specific antibody α-dsDNA. For the 
dsDNA detection samples were digested with proteinase K, diluted in Tris/Borate/EDTA (TBE) 
buffer, and applied to nylon membrane (Hybond N+).  
 
Colony forming assay 
Cell survival after exposure to CPT, Eto, FA or methylglyoxal was determined by standard 
clonogenic assay. In brief, cells were seeded in 6-well plates and incubated overnight. Cells were 
exposed to increase doses of the drugs diluted in DMEM, washed and incubated again in fresh 
medium. Cells were exposed for 24 hours with CPT and methylglyoxal, 1 hour with Eto and 20 
minutes with FA. Colonies were fixed 7-10 days later, and the number of clones was counted using 
the automated colony counter GelCount™ (DTI-Biotech). The number of colonies in treated samples 
was expressed as a percentage of colony numbers in the untreated samples. 
 
	  Cell viability assay 
Cell viability assay was performed with resazurin dye according to the manufacturer’s instructions 
(Cell signalling). 
 
Cell cycle analysis 
For flow cytometry analysis, 0.2 x 106 – 0.5 x 106 cells were harvested by centrifugation and fixed in 
ice-cold methanol, followed by resuspension in Phosphate-buffered saline (PBS) containing 1% 
Bovine serum albumin (BSA), 20 µg/ml of propidium iodide or 10 µg/ml DAPI and 10 µg/ml of 
RNase A. Flow cytometry was performed on a FACScalibur instrument (BD Biosciences). Cell-cycle 
phase distributions were analyzed using FlowJo software. Please describe here in brief or cite a paper 
for thymidine block and release. 
 
Cell cycle synchronization 
HeLa cells were synchronized at G1/S of the cell cycle by double thymidine treatment, as described 
previously(Harper, 2005). T24 cells were synchronized as described previously (Jin et al., 1997). 
 
 
Protein purification 
For overexpression in E.coli cells SPRTN constructs were cloned in to either the pNIC-ZB vector 
(full length SPRTN-WT, SPRTN-E112A, and SPRTN-Y117C), or pNIC28-Bsa4 vector (all other 
truncated constructs). For purification of full length constructs containing a TEV cleavable Z-basic-
his tag, cell pellets were thawed and resuspended in lysis buffer (100 mM HEPES pH 7.5, 500 mM 
NaCl, 10% glycerol, 10 mM imidazole, 1 mM Tris (2-carboxyethyl) phosphene (TCEP), 0.1% DDM, 
1 mM MgCl, 1 x set III protease inhibitors (Merck). Cells were lysed by sonication and 1 unit of 
Benzonase was added to lysates before the cell were debris pelleted by centrifugation. Lysates were 
applied to a Ni-sepharose IMAC gravity flow column, washed with 2 column volumes of wash buffer 
(50 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 45 mM imidazole, 1 mM TCEP), and eluted in 
elution buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 300 mM imidazole, 1 mM 
TCEP). Elution fractions were applied directly to a 5ml Hitrap SP HP column (GE healthcare), 
washed with wash buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 1 mM TCEP) and eluted with 
elution buffer (50 mM HEPES pH 7.5, 1M NaCl, 1 mM TCEP). The purification tag was cleaved with 
the addition of 1:20 mass ratio of His-tagged TEV protease during overnight dialysis into buffer A (20 
mM HEPES, pH 7.5, 500 mM NaCl, 0.5 mM TCEP). Samples were concentrated by ultrafiltration 
using a 30 kDa molecular weight cut off centrifugal concentrator and loaded on to size exclusion 
chromatography using a HiLoad 16/60 Superdex 200 column at 1 ml/min in buffer A. The same 
protocol was used for purification of the truncated constructs with the exception of the omission of the 
SP HP column and the inclusion of a Ni-sepharose rebind following TEV cleavage (to remove his-
	  tagged TEV protease). Protein identities were verified by LC/ESI-TOF Mass spectrometry and protein 
concentrations were determined by absorbance at 280nm (Nanodrop) using the calculated molecular 
mass and extinction coefficients. 
 
Fluorescence polarisation DNA binding assays and DNA probe annealing 
DNA binding was measured using a fluorescence polarisation based assay. DNA oligonucleotides 
with the sequences as follows  
OD1 - ATC GAT AGT CGG ATC CTC TAG ACA GCT CCA TGT AGC AAG GCA CTG GTA 
GAA TTC GGC AGC GTC,  
OD2 - GAC GCT GCC GAA TTC TAC CAG TGC CTT GCT ACA TGG AGC TGT CTA GAG 
GAT CCG ACT ATC GAT, and  
OD3 - GAC GCT GCC GAA TTC TAC CAG TGC CTT GCT AGG ACA TCT TTG CCC ACC 
TGC AGG TTC ACC C were mixed together at a 10 µM concentration in a buffer consisting of 10 
mM HEPES pH 7.5, 50 mM NaCl in the following combinations, single stranded (ss) =OD1, double 
stranded (ds) OD1+OD2 and splayed duplex OD1+OD3. For all substrates the OD1 oligo was 
labelled on the 5’ end with Fluorescein isothiocyanate and substrates were formed by heating 96°C 
and allowing to cool on a heat block over 2 hrs. Probes were used at a final concentration of 10 nM 
and binding experiments were performed in a buffer containing 10 mM HEPES pH 7.5, 150 mM 
NaCl, with varying protein concentration. Measurements were performed in 384 well plates (30 µl 
final volume) in a POLARstar plate reader (BMG Labtech) with excitation at 485 nm and emission at 
520 nm. Kinetic constants were calculated from binding curves using a 4 parameter logarithmic 
binding equation using the program PRISM (GraphPad). 
 
In vitro self –cleavage assays 
SPRTN self-cleavage assays were performed in 20 µl reaction volume, containing 2 µl SPRTN (1 
mg/ml), 10 µl of reaction buffer (25 mM Tris pH 7.5, 150 mM NaCl), 6 µl H2O, and 1 µl DNA (10 
µM). Several types of DNA probes were used for induction of cleavage, ssDNA and dsDNA of 
various lengths: 100, 32, 16, and 8 bp. Samples were incubated for 2 hours at 37°C, and stopped by 
the addition of 2X Laemmli buffer and resolved by SDS-PAGE followed by coomassie blue staining. 
 
In vitro cleavage of the SPRTN substrates  
SPRTN enzymatic reactions with histones were performed in 150 mM NaCl, 25 mM Tris pH 7.4 in a 
PCR block at 37°C. The reaction volume was typically 10 µl and contained: E. coli purified 
recombinant SPRTN (1 – 10 mg/ml solution), substrate (typically 1 mg/ml solution) and 100 bp long 
dsDNA oligonucleotide probe (OD4 
ACGCGGGTTAGCGGTACCCAGTCCAGTGACCTAGGCAGCTTTAAGCTAGTACGACTTGCT
TAGATTGCAGTCGACGACGTAGCTGGCATAGAGGTACAGC) (40 µM stock solution) in 
	  Klenow buffer without DTT. Conditions for cleavage reactions of histones were performed with the 
3:1 molar ratio of SPRTN:substrate and 15:1 molar ratio of SPRTN: dsDNA in a 10µl volume. The 
cleavage reactions for Topo1 and Topo2α were performed in 16 µl volume and 30:1 molar ratio of 
SPRTN : dsDNA. Reactions were incubated for 20h at 37˚C and stopped by the addition of 2X 
Laemmli buffer. Reactions were resolved by SDS-PAGE followed by western blotting with substrate 
specific antibody. The enzyme (SPRTN) loading was monitored with α-SPRTN (N-terminal) in each 
reaction mixture. 
 
In vitro DPCs cleavage 
DPCs were prepared according to the SDS/KCl precipitation assasy with the following modifications. 
Samples were washed in buffer containing 200 mM KCl, 20 mM Tris (pH 7.5), and DPCs were 
separated from total proteins using the QIAquick PCR Purification Kit (Qiagen). In vitro DPC 
cleavage was performed in 150 mM NaCl, 25 mM Tris pH 7.4 in a PCR block at 37°C for 3 hours. 
The reaction volume was typically 20 µl and contained 10 µg of DPCs and 1 µg of recombinant 
SPRTN protein. Reactions were stopped by the addition of 2X Laemmli buffer, resolved by SDS-
PAGE and visualized by silver staining.  
Immunoprecipitation 
To isolate Topo1 and Topo2α, HEK293T cells were transiently transfected with GFP-Topo2α or 
YFP-Topo1 using PEI (polyethyleneimine) reagent (Tom et al., 2008). Both proteins were 
immunoprecipitated using GFP-trap beads (Chromotek) in denaturing conditions (1% SDS, 5mM 
EDTA). Cell lysates were digested overnight with benzonase nuclease (Sigma) to further solubilize 
the sample. Sonication was avoided due to the fact that it disrupts binding of YFP-Topo1 or GFP-
Topo2α to the GFP beads. Samples were diluted ten times in the IP buffer (150 mM NaCl, 10 mM 
Tris, 0.5 mM EDTA pH 7.5) with 1% Triton and precleared with bab-20 beads (Chromotek) for 30 
min at 4°C. After discarding the bab-20 beads (50 G, 30 sec centrifugation), precleared samples were 
incubated with GFP beads (Chromotek) for 4h at 4°C, followed by five washes in the IP buffer. Cells 
were treated with 10 µM CPT or 25 µM ETO for 1h, when indicated. 
 
Co-immunoprecipitation 
To isolate SPRTN-interacting proteins, lysates from Flp-In 293 cells upon doxycycline induction of 
SPRTN-WT-SSH (Strep-Strep-HA tag) were prepared. Samples were lysed in 1% Triton, 150 mM 
NaCl, 50 mM Tris, 1mM EDTA pH 7.4 for 1h at 4°C with 10 mM NEM and protease and 
phosphatase inhibitor cocktails (ThermoFisher Scientific) and avidin (IBA), followed by 
centrifugation at 16,000 g for 10 min. The pellet was digested with nuclease benzonase in the 
bensonase buffer (Invitrogen) including protease and phosphatase inhibitor cocktail, overnight at 4°C. 
Both fractions were pooled and diluted 10 times in IP buffer (150 mM NaCl, 50 mM Tris, pH 8) 
	  followed by preclearing of the lysate with blank sepharose (IBA) for 1h at 4°C. Samples were 
incubated with Strep-Tactin sepharose (IBA) for 2h at 4°C, washed 5 times in IP buffer containing 
0.05% NP-40 and eluted in 2X Laemmli for 10 min at 95°C. 
 
Cellular fractionation 
Cellular fractionation was performed as previously described (Mendez and Stillman, 2000) with the 
slight modifications as follows: after isolation of cytosolic and nuclear soluble fractions, the 
chromatin fraction was digested with benzonase 1µl of benzonase (200u/ml) in a buffer containing 50 
mM Tris, pH 7.9, 50 mM NaCl and 5 mM KCl overnight at 4˚C with gentle agitation.  
 
Isolation of Proteins On Nascent DNA (iPOND) 
iPOND was performed as described in (Sirbu et al., 2012) with the following modifications. Newly 
synthesized DNA in HEK293 or HeLa wild-type or SPRTN-knockout cells (~2 x 108 cells per 
condition) was labelled via incubation with 10 µM Edu for 10 and 15 minutes, respectively. For 
thymidine chases, cell culture media was supplemented with 10 µM thymidine and incubated for 2 or 
10 minutes as indicated.  HEK293 cells were synchronised by double thymidine block, and washed 
thoroughly with 1 x PBS followed by cell culture media and released into S-phase for 4 hours before 
EdU labelling. For experiments in HEK293 cells, chromatin was fragmented into 50-300 bp 
fragments by sonication with a Bioruptor Plus sonicator (30 seconds ON, 30 seconds OFF for 50 
cycles). In HeLa cells, chromatin was fragmented into 400 bp fragments (30 seconds ON, 30 seconds 
OFF for 5 cycles). To isolate proteins on Edu-labelled DNA, samples from incubated overnight with 
streptavidin-coupled agarose beads (Merck Millipore). Aliquots of each extract were kept for loading 
controls. 
 
DNA fiber assay 
The DNA fiber assay was performed as described previously (Lessel et al., 2014). Briefly, 
asynchronous LCL or HeLa cells were labelled with 30 µM of CldU (Sigma, C6891) for 30 min, and 
then labelled with 250 µM of IdU (Sigma, 17125) for an additional 30 min. HeLa cells were washed 3 
times with warm PBS after 1st nucleotide (CldU) incubation. DNA replication was inhibited by 
treating cells with ice-cold PBS. Cells were lysed in 200 mM Tris-HCl pH 7.4, 50 mM EDTA and 
0.5% SDS, DNA fibers were spread onto glass slides, fixed with 3:1 methanol and acetic acid, 
denatured with 2.5 M HCl, blocked with 2% BSA and stained with anti-rat and anti-mouse 5-bromo-
2′-deoxyuridine (BrdU) that specifically recognize either CldU (Abcam-Ab6326, dilution 1:500) or 
IdU (BD- 347580, dilution 1:100). Anti-rat Cy3 (dilution 1:300, Jackson Immuno Research, 712-116-
153) and anti-mouse Alexa-488 (dilution 1:300, Molecular Probes, A11001) were used as the 
respective secondary antibodies. Microscopy was done using a Leica DMRB microscope with a 
	  DFC360FX camera. The lengths of the CldU- and IdU-labelled tracts were measured by ImageJ 
software and converted into micron scale. Statistical analysis was done by GraphPad Prism software 
using unpaired t-test. Mean value was then converted into kilo base (1µm = 2.59 kb) to precisely 
determine the replication fork speed as shown previously (Petermann et al., 2010). For the DNA fiber 
assay under genotoxic stress, the second nucleotide (IdU) was either mock treated or incubated in the 
presence of 25 nM CPT or 50 µM formaldehyde (30 min). 
 
Mass spectrometry 
Mass Spectrometry of Intact Proteins  
For mass spectrometry under denaturing conditions 50-µl protein samples were injected at ~0.02 
mg/ml in 0.1% formic acid onto a 2.1 mm x 12.5 mm Zorbax 5 µm 300SB-C3 guard column 
(Agilent) resolved by reversed-phase chromatography at 40 °C. The solvent system was 0.1% formic 
acid in LC-MS grade water (buffer A) and 0.1% formic acid in LC-MS grade methanol (buffer B), 
and proteins were eluted with a linear gradient of 5–95% buffer B over 1.5 min at 1.0 ml/min. Protein 
masses were determined using an Agilent 6530 QTOF. The analysis of MS spectra was performed in 
ICP-MS MassHunter Software (Agilent). Analysis of histone and SPRTN peptides was done using 
Protein Analysis Worksheet (PAWS). Only cleavage products (CPs) which could be determined with 
high confidence (unique peptide matches, ppm 50) are taken into consideration for the analysis of 
SPRTN cleavage site. Histone protein sequences H2A (AAN59960.1), H2B (AAN59961.1), H3 
(NP_002098.1) and H4 (NP_778224) without initial Methionine residue corresponded to the 
recombinant protein molar mass as stated by the manufacturer (NEB). For mass spectrometry under 
native conditions protein samples, 50 µl at 1 mg/ml were buffer exchanged into a buffer consisting of 
50 mM ammonium acetate pH 6.5, and injected directly at a flow rate of 6 µl per minute. Protein 
masses were determined using an Agilent 6530 QTOF. 
Mass spectrometry for the identification of proteins crosslinked to the DNA  
DPCs were isolated as described previously. Equal amounts of DNA were digested with benzonase 
(Invitrogen) for 60 minutes at 37°C. Proteins were precipitated by standard Trichloroacetic Acid 
(TCA) protocol and ressuspend in 6M urea solution. Proteins were then reduced with dithiothreitol (5 
mM) alkylated with iodoacetamide (20 mM) and precipitated again via standard methanol/chloroform 
extraction. Proteins were resuspended in 50 ml 6M urea and urea was adjusted to a final concentration 
of 1 M. Samples were digested at 37 °C ON with trypsin. Peptides were purified using SEP-C18 
purification columns and peptides dry using speed vac. Dried tryptic peptides were reconstituted in 
15µl of LC-MS grade water containing 2% acetonitrile and 0.1% trifluoroacetic acid. Samples were 
subsequently analysed by nano-liquid chromatography tandem mass spectrometry (LC-MS/MS) using 
a Dionex Ultimate 3000 UPLC coupled to a Q Exactive hybrid quadrupole orbitrap mass spectrometer 
(ThermoFisher Scientific) as described previously (Chung et al., 2016; Lochmatter et al., 2016; 
Michalski et al., 2011). Briefly, peptides were desalted on a PepMapC100 column (100µm x 20mm, 
	  5µm particle size, ThermoFisher Scientific) for 3minute at a flow rate of 8 µl/min and separated on a 
directly coupled nEASY column (PepMap C18, 75 µm x 500mm, 2 µm particle, ThermoFisher 
Scientific) using a multistep gradient starting with 3 min at 2% Acetonitrile in 5% DMSO with 0.1% 
Formic acid (buffer B), followed by 60 min linear gradient up to 35% buffer B at 250nl/min flow rate, 
7 min linear gradient up to 99% buffer B and maintained at 99% buffer B for 5 min at a flow rate of 
250nl/min before reverting to 2% buffer B for 3 min prior to a last 4 min at 99% solvent B. Full MS 
scans were acquired over the m/z range of 380 - 1800 at a resolution of 70,000 at 200m/z (AGC target 
of 3x106 ions). MS/MS data was acquired in a data dependent manner by selecting the 15 most 
abundant precursor ions for HCD fragmentation (CE of 28) and on MS/MS resolution of 17,500. 
 
Quantitative proteomics and data analysis  
Label-free quantitation was used to identify overexpressed proteins in SPRTN depleted cells. Raw 
LC-MS/MS data was uploaded into Progenesis QI Proteomics v2.0 software (Waters). After sample 
runs alignment, filtering, peak detection and   quantification/normalisation (using default parameters), 
a peak list containing all peptide precursor ions detected across all experimental conditions and 
biological replicates was generated and exported as mgf file. Peptide and protein identifications was 
performed using MASCOT v2.5. Data was searched against the Human UniProt SwissProt database 
(20,268 Homo sapiens sequences; retrieved 20151126) using the Decoy function, whilst selecting 
trypsin as enzyme (allowing 1 miscleavages), peptide charge of +2, +3, +4 ions, peptide tolerance of 
10 ppm and MS/MS of 0.05 Da; #13C at 1; Carboamidomethylation as fixed modification, and 
Oxidation (M) and Deamidation (N and Q) as a variable modification. MASCOT data search results 
were filtered using ion score cut off at 20 and a false discovery rate (FDR) of 1%. Filtered data was 
imported into Progenesis for subsequent revision of normalization and statistical analysis. Only 
proteins identified with at least two peptides (peptide counts) and quantified with at least two peptides 
(unique peptides) were considered for statistical analysis. Differentially expressed proteins and in 
particular proteins overexpressed in SPRTN depleted cells were selected by p-Anova p<0.05 and fold 
change. The gene ontology tool (PANTHER; Protein ANalysis THrough Evolutionary relationships, 
version 10.) was used to determine the protein function class of the proteins significantly 
overexpressed in SPRTN depleted cells.   
 
Statistical analysis 
Statistical analysis was done by GraphPad Prism software using unpaired t-test or as otherwise 
described under individual methods subheadings. p value = ns; non-significant, *p < 0.05, **p < 0.01 
and ***p < 0.001. 
 
In silico methods 
Disordered protein regions were predicited using PONDR-FIT (Xue et al., 2010). 
	  DNA binding residues were predicted using MetaDBsite (Si et al., 2011). 
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